2024
Ex vivo drug susceptibility and resistance mediating genetic polymorphisms of Plasmodium falciparum in Bobo-Dioulasso, Burkina Faso
Somé A, Conrad M, Kabré Z, Fofana A, Yerbanga R, Bazié T, Neya C, Somé M, Kagambega T, Legac J, Garg S, Bailey J, Ouédraogo J, Rosenthal P, Cooper R. Ex vivo drug susceptibility and resistance mediating genetic polymorphisms of Plasmodium falciparum in Bobo-Dioulasso, Burkina Faso. Antimicrobial Agents And Chemotherapy 2024, 68: e01534-23. PMID: 38411062, PMCID: PMC10989024, DOI: 10.1128/aac.01534-23.Peer-Reviewed Original ResearchResistance to antifolatesUncomplicated malariaEx vivo drug susceptibilityArtemisinin partial resistanceMonthly sulfadoxine-pyrimethaminePfcrt K76TPfK13 propeller domainResistance-mediating polymorphismsSeasonal malaria chemopreventionTreating uncomplicated malariaResistance to cycloguanilHigh-level resistancePlasmodium falciparum</i>A581GA613S mutationsPfdhps mutationsPfmdr1 N86YArtemether-lumefantrineK76TSulfadoxine-pyrimethamineMalaria chemopreventionPrevent malariaBobo-DioulassoDrug susceptibilityPrincipal therapy
2022
Long-term effects of increased adoption of artemisinin combination therapies in Burkina Faso
Zupko R, Nguyen T, Somé A, Tran T, Gerardin J, Dudas P, Giang D, Tran K, Wesolowski A, Ouédraogo J, Boni M. Long-term effects of increased adoption of artemisinin combination therapies in Burkina Faso. PLOS Global Public Health 2022, 2: e0000111. PMID: 36962300, PMCID: PMC10021447, DOI: 10.1371/journal.pgph.0000111.Peer-Reviewed Original ResearchMultiple first-line therapiesFirst-line therapyTreatment failure rateArtemether-lumefantrineFalciparum malariaCombination therapyLong-term effectsEqual long-term outcomesLower treatment failure rateUncomplicated Plasmodium falciparum malariaMajor global public health concernGlobal public health concernPlasmodium falciparum malariaP. falciparum malariaLong-term outcomesArtemisinin combination therapyP. falciparum transmissionPublic health concernMalaria settingsTreatment failureFailure rateHigh burdenTreatment efficacyACT useDrug resistance
2021
Persistent Submicroscopic Plasmodium falciparum Parasitemia 72 Hours after Treatment with Artemether-Lumefantrine Predicts 42-Day Treatment Failure in Mali and Burkina Faso
Beshir K, Diallo N, Somé F, Sombie S, Zongo I, Fofana B, Traore A, Dama S, Bamadio A, Traore O, Coulibaly S, Maurice O, Diarra A, Kaboré J, Kodio A, Togo A, Dara N, Coulibaly M, Dao F, Nikiema F, Compaore Y, Kabore N, Barry N, Soulama I, Sagara I, Sirima S, Ouédraogo J, Djimde A, Sutherland C. Persistent Submicroscopic Plasmodium falciparum Parasitemia 72 Hours after Treatment with Artemether-Lumefantrine Predicts 42-Day Treatment Failure in Mali and Burkina Faso. Antimicrobial Agents And Chemotherapy 2021, 65: 10.1128/aac.00873-21. PMID: 34060901, PMCID: PMC8284475, DOI: 10.1128/aac.00873-21.Peer-Reviewed Original ResearchConceptsArtemether-lumefantrineClinical episodesFirst treatment episodeComplete parasite clearanceDrug treatment groupPlasmodium falciparum parasitemiaQuantitative PCRMalaria transmission intensityEvaluable patientsParasitological efficacyParasite clearanceTreatment failureSubmicroscopic parasitemiaTreatment episodesTreatment outcomesTreatment groupsBetter efficacyDay 42Short intervalsH posttreatmentParasitemiaRegimensPatientsBurkina FasoTransmission intensityHepatic safety of repeated treatment with pyronaridine‐artesunate versus artemether–lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso
Compaoré Y, Zongo I, Somé A, Barry N, Nikiéma F, Kaboré T, Ouattara A, Kabré Z, Wermi K, Zongo M, Yerbanga R, Sagara I, Djimdé A, Ouédraogo J. Hepatic safety of repeated treatment with pyronaridine‐artesunate versus artemether–lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso. Malaria Journal 2021, 20: 64. PMID: 33514368, PMCID: PMC7847156, DOI: 10.1186/s12936-021-03593-6.Peer-Reviewed Original ResearchConceptsHepatic adverse eventsArtemether-lumefantrineAL armAdverse eventsElevated ALTMalaria episodesUncomplicated malariaHepatic safetyDirect bilirubinPA armFirst-line anti-malarial drugHepatic safety profileUncomplicated malaria episodesElevated total bilirubinBobo-DioulassoLogistic regression modelsAnti-malarial drugsAlkaline phosphataseSubsequent malariaUnscheduled daysStudy armsSafety profileResultsA totalClinical trialsTotal bilirubin
2020
Efficacy of artemether-lumefantrine and artesunate-amodiaquine as first line therapy of uncomplicated malaria in Burkina Faso, 11 years after policy change
Zongo I, Compaoré Y, Nikiéma F, Zongo M, Barry N, Somé F, Kaboré N, Ouédraogo J. Efficacy of artemether-lumefantrine and artesunate-amodiaquine as first line therapy of uncomplicated malaria in Burkina Faso, 11 years after policy change. Pan African Medical Journal 2020, 35: 68. PMID: 32537072, PMCID: PMC7250195, DOI: 10.11604/pamj.2020.35.68.20849.Peer-Reviewed Original ResearchConceptsFirst-line therapyLine therapyUncomplicated malariaPolymerase chain reactionTreatment efficacyEarly treatment failureGood tolerability profileFirst-line treatmentParasitological responsePrimary endpointTolerability profileArtemether-lumefantrineTreatment failureLine treatmentASAQ groupDay 28Better efficacyBurkina FasoTherapyMalariaEfficacyChain reactionCompletion ratesTreatmentDaysThe duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data
Bretscher M, Dahal P, Griffin J, Stepniewska K, Bassat Q, Baudin E, D’Alessandro U, Djimde A, Dorsey G, Espié E, Fofana B, González R, Juma E, Karema C, Lasry E, Lell B, Lima N, Menéndez C, Mombo-Ngoma G, Moreira C, Nikiema F, Ouédraogo J, Staedke S, Tinto H, Valea I, Yeka A, Ghani A, Guerin P, Okell L. The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data. BMC Medicine 2020, 18: 47. PMID: 32098634, PMCID: PMC7043031, DOI: 10.1186/s12916-020-1494-3.Peer-Reviewed Original ResearchConceptsFirst-line treatmentDuration of chemoprophylaxisPost-treatment prophylaxisIndividual patient dataAS-AQArtemether-lumefantrinePlasmodium falciparum malaria casesPfcrt 76TPatient dataFalciparum malaria casesPotential public health impactHigh transmission areasDuration of protectionLonger protectionPublic health impactTransmission intensityWild-type Pfmdr1Pfmdr1 86YMalaria morbidityClinical incidenceMean durationClinical trialsChemoprevention programMultivariable modelHigh prevalenceIn vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso
Lingani M, Bonkian L, Yerbanga I, Kazienga A, Valéa I, Sorgho H, Ouédraogo J, Mens P, Schallig H, Ravinetto R, d’Alessandro U, Tinto H. In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso. Malaria Journal 2020, 19: 8. PMID: 31906948, PMCID: PMC6945612, DOI: 10.1186/s12936-019-3089-z.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAmodiaquineAntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsArtesunateBurkina FasoChildChild, PreschoolDrug CombinationsDrug Therapy, CombinationFemaleHumansInfantInhibitory Concentration 50LumefantrineMalaria, FalciparumMaleMass Drug AdministrationPlasmodium falciparumTreatment FailureTreatment OutcomeConceptsFirst-line treatmentArtemether-lumefantrineUncomplicated malariaFalciparum malariaTreatment failureOverall adverse event incidenceUncomplicated Plasmodium falciparum malariaEx vivo efficacyUnadjusted cure rateAdverse event incidenceUncomplicated falciparum malariaPlasmodium falciparum malariaP. falciparum susceptibilityMalaria-endemic areasEx vivo susceptibilityMass drug administrationP. falciparum isolatesEx vivo analysisAL armASAQ armOpen labelPrimary endpointRecurrent parasitaemiaEvent incidenceTreatment arms
2019
Evaluation of the effects on the QT-interval of 4 artemisinin-based combination therapies with a correction-free and heart rate-free method
Funck-Brentano C, Ouologuem N, Duparc S, Felices M, Sirima S, Sagara I, Soulama I, Ouedraogo J, Beavogui A, Borghini-Fuhrer I, Khan Y, Djimdé A, Voiriot P. Evaluation of the effects on the QT-interval of 4 artemisinin-based combination therapies with a correction-free and heart rate-free method. Scientific Reports 2019, 9: 883. PMID: 30696921, PMCID: PMC6351684, DOI: 10.1038/s41598-018-37113-5.Peer-Reviewed Original ResearchConceptsArtemisinin-based combination therapyQTc prolongationHeart rate changesCombination therapyVentricular repolarizationQT/QTc interval prolongationEvidence of proarrhythmiaQTc interval prolongationQTc assessmentLethal ventricular arrhythmiasExtent of prolongationMalaria crisisArtemether-lumefantrineInterval prolongationVentricular arrhythmiasAfrican patientsClinical safetyFirst episodeQT intervalHeart rateAntimalarial drugsProlongationQT correctionECG recordingsHigh-quality ECG recording
2018
Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial
Drugs T, Sagara I, Beavogui A, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, Traore A, Diallo N, Diakite H, Togo A, Koumare S, Keita M, Camara D, Somé A, Coulibaly A, Traore O, Dama S, Goita S, Djimde M, Bamadio A, Dara N, Maiga H, Sidibe B, Dao F, Coulibaly M, Alhousseini M, Niangaly H, Sangare B, Diarra M, Coumare S, Kabore M, Ouattara S, Barry A, Kargougou D, Diarra A, Henry N, Soré H, Bougouma E, Thera I, Compaore Y, Sutherland C, Sylla M, Nikiema F, Diallo M, Dicko A, Picot S, Borrmann S, Duparc S, Miller R, Doumbo O, Shin J, Gil J, Björkman A, Ouedraogo J, Sirima S, Djimde A. Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. The Lancet 2018, 391: 1378-1390. PMID: 29606364, PMCID: PMC5889791, DOI: 10.1016/s0140-6736(18)30291-5.Peer-Reviewed Original ResearchConceptsArtemisinin-based combination therapyFirst-line artemisinin-based combination therapyArtemether-lumefantrineDay 28Day 42Study drugUncomplicated malariaMalaria episodesEligible participantsIncidence ratePan African Clinical Trials RegistryUncomplicated P falciparum malariaCurrent first-line therapyAfrican Clinical Trials RegistryDeveloping Countries Clinical Trials PartnershipDihydroartemisinin-piperaquine treatmentFirst malaria episodeP falciparum malariaUncomplicated malaria episodesFirst-line therapyHistory of feverClinical Trials RegistryNon-falciparum speciesMild transient elevationUK Medical Research Council
2017
TO VALUE THE EFFICIENCY OF PYRONARIDINE-ARTESUNATE AND ARTEMETHER-LUMEFANTRINE IN THE TREATMENT OF UNCOMPLICATED MALARIA OF PLASMODIUM SPP. IN BURKINA FASO
Barry N, Kaboré N, Kabré Z, Fofana A, Nikèma F, Compaoré D, Somé F, Zongo I, Djimdé A, Ouédraogo J. TO VALUE THE EFFICIENCY OF PYRONARIDINE-ARTESUNATE AND ARTEMETHER-LUMEFANTRINE IN THE TREATMENT OF UNCOMPLICATED MALARIA OF PLASMODIUM SPP. IN BURKINA FASO. BMJ Global Health 2017, 2: a24. DOI: 10.1136/bmjgh-2016-000260.62.Peer-Reviewed Original ResearchArtemether-lumefantrineUncomplicated malariaTreatment failurePA groupAL groupEffective malaria vaccineStandard of careNew therapeutic drugsPyronaridine-ArtesunateMalaria vaccinePatient groupTherapeutic failureFirst episodeTreatment responseDay 28Malaria diagnosisDay 42Burkina FasoMalaria controlEvidence baseLess casesPlasmodium sppTherapeutic drugsMalariaBobo-DioulassoComparison of effectiveness of two different artemisinin-based combination therapies in an area with high seasonal transmission of malaria in Burkina Faso
Sondo P, Derra K, Nakanabo S, Tarnagda Z, Kazienga A, Valea I, Sorgho H, Ouédraogo J, Guiguemdé T, Tinto H. Comparison of effectiveness of two different artemisinin-based combination therapies in an area with high seasonal transmission of malaria in Burkina Faso. Annals Of Parasitology 2017, 63: 127-131. PMID: 28822205, DOI: 10.17420/ap6302.96.Peer-Reviewed Original ResearchConceptsArtemether-lumefantrine groupsCure rateArtemether-lumefantrineHigh incidenceDifferent artemisinin-based combination therapiesMalaria transmissionPost-treatment prophylactic effectRandomized open-label trialArtemisinin-based combination therapyArtesunate-amodiaquine treatmentHigh seasonal transmissionUncorrected cure ratesOpen-label trialUncomplicated falciparum malariaMerozoite surface protein 1Surface protein 1Antimalarial regimensArtesunate-AmodiaquinePCR adjustmentLabel trialUncomplicated malariaFalciparum malariaMalaria episodesRecurrent parasitaemiaComparison of effectiveness
2015
Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial
Sagara I, Beavogui A, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, Camara D, Somé A, Coulibaly A, Traore O, Dara N, Kabore M, Thera I, Compaore Y, Sylla M, Nikiema F, Diallo M, Dicko A, Gil J, Borrmann S, Duparc S, Miller R, Doumbo O, Shin J, Bjorkman A, Ouedraogo J, Sirima S, Djimdé A. Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial. The Lancet Infectious Diseases 2015, 16: 189-198. PMID: 26601738, PMCID: PMC4726763, DOI: 10.1016/s1473-3099(15)00318-7.Peer-Reviewed Original ResearchConceptsSubstudy analysisFirst episodeFirst treatmentArtemisinin-based combination treatmentDeveloping Countries Clinical Trials PartnershipPrimary safety endpointPyronaridine-artesunate efficacyHistory of feverIncidence of hepatotoxicityAdverse event frequencyExclusion of patientsUK Medical Research CouncilMedical Research CouncilParasitological responseSafety endpointArtemether-lumefantrineMalaria episodesTreat analysisAfrican patientsMalaria treatmentClinical trialsMalaria VentureLaboratory valuesAlanine aminotransferaseHealth facilitiesEffectiveness and safety of artemether–lumefantrine versus artesunate–amodiaquine for unsupervised treatment of uncomplicated falciparum malaria in patients of all age groups in Nanoro, Burkina Faso: a randomized open label trial
Sondo P, Derra K, Diallo-Nakanabo S, Tarnagda Z, Zampa O, Kazienga A, Valea I, Sorgho H, Owusu-Dabo E, Ouedraogo J, Guiguemde T, Tinto H. Effectiveness and safety of artemether–lumefantrine versus artesunate–amodiaquine for unsupervised treatment of uncomplicated falciparum malaria in patients of all age groups in Nanoro, Burkina Faso: a randomized open label trial. Malaria Journal 2015, 14: 325. PMID: 26289949, PMCID: PMC4545998, DOI: 10.1186/s12936-015-0843-8.Peer-Reviewed Original ResearchConceptsArtemisinin-based combination therapyOpen-label trialArtemether-lumefantrineYears of ageDrug intakeLabel trialDay 28Randomized open-label trialAge groupsNanoro health districtUncomplicated falciparum malariaMerozoite surface protein 1Primary health centersSurface protein 1Mode of administrationAnti-malarial drugsParents/guardiansParasitological responseUncomplicated malariaAdverse eventsFalciparum malariaMalaria episodesOlder patientsCombination therapyCure rate
2014
Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for P. falciparum Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine
Venkatesan M, Gadalla N, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, Price R, Mårtensson A, Rosenthal P, Dorsey G, Sutherland C, Guérin P, Davis T, Ménard D, Adam I, Ademowo G, Arze C, Baliraine F, Berens-Riha N, Björkman A, Borrmann S, Checchi F, Desai M, Dhorda M, Djimdé A, El-Sayed B, Eshetu T, Eyase F, Falade C, Faucher J, Fröberg G, Grivoyannis A, Hamour S, Houzé S, Johnson J, Kamugisha E, Kariuki S, Kiechel J, Kironde F, Kofoed P, LeBras J, Malmberg M, Mwai L, Ngasala B, Nosten F, Nsobya S, Nzila A, Oguike M, Otienoburu S, Ogutu B, Ouédraogo J, Piola P, Rombo L, Schramm B, Somé A, Thwing J, Ursing J, Wong R, Zeynudin A, Zongo I, Plowe C, Sibley C, Asaq Molecular Marker Study Group. Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for P. falciparum Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine. American Journal Of Tropical Medicine And Hygiene 2014, 91: 833-843. PMID: 25048375, PMCID: PMC4183414, DOI: 10.4269/ajtmh.14-0031.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SubstitutionAmodiaquineAntimalarialsArtemetherArtemisininsChildChild, PreschoolChloroquineDatasets as TopicDrug CombinationsDrug ResistanceDrug Therapy, CombinationEthanolaminesFluorenesGenetic MarkersGenotypeHumansInfantKaplan-Meier EstimateLumefantrineMalaria, FalciparumMembrane Transport ProteinsMultidrug Resistance-Associated ProteinsPlasmodium falciparumPolymorphism, GeneticProtozoan ProteinsRisk FactorsConceptsArtemether-lumefantrineP. falciparum multidrug resistance 1 genePlasmodium falciparum chloroquine resistance transporterPfmdr1 copy numberArtemisinin combination therapyIndividual patient dataChloroquine resistance transporterMultidrug resistance 1 geneWorldWide Antimalarial Resistance NetworkParasitologic cureCombination therapyParasite polymorphismsPartner drugsTherapeutic responseClinical trialsRelevant outcomesArtemisinin componentPatient dataResistance transporterStandardized methodPolymorphismPatientsPfmdr1PfcrtAmodiaquineEffectiveness of artesunate–amodiaquine vs. artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in Nanoro, Burkina Faso: a non‐inferiority randomised trial
Tinto H, Diallo S, Zongo I, Guiraud I, Valea I, Kazienga A, Kpoda H, Sorgho H, Ouédraogo J, Guiguemdé T, D'Alessandro U. Effectiveness of artesunate–amodiaquine vs. artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in Nanoro, Burkina Faso: a non‐inferiority randomised trial. Tropical Medicine And International Health 2014, 19: 469-475. PMID: 24494602, DOI: 10.1111/tmi.12274.Peer-Reviewed Original ResearchConceptsArtemether-lumefantrineUncomplicated malariaFalciparum malariaUncomplicated falciparum malariaLow cure rateParents/guardiansAL armASAQ armParasitological responseFirst doseStudy nursesStudy armsRecrudescent infectionsCombination therapyCure rateTreatment administrationEndemic countriesDay 28Efficacy studiesNew infectionsDay 14Routine practiceMalariaBurkina FasoASAQ
2007
Randomized Comparison of Amodiaquine plus Sulfadoxine-Pyrimethamine, Artemether-Lumefantrine, and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Burkina Faso
Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Séré Y, Rosenthal P, Ouédraogo J. Randomized Comparison of Amodiaquine plus Sulfadoxine-Pyrimethamine, Artemether-Lumefantrine, and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Burkina Faso. Clinical Infectious Diseases 2007, 45: 1453-1461. PMID: 17990228, DOI: 10.1086/522985.Peer-Reviewed Original ResearchConceptsUncomplicated Plasmodium falciparum malariaPlasmodium falciparum malariaFalciparum malariaArtemether-lumefantrineRecurrent parasitemiaUncomplicated P. falciparum malariaCombination antimalarial therapyEarly treatment failureSerious adverse eventsP. falciparum malariaDrug-resistant parasitesYears of ageMonths of ageAntimalarial regimenDihydroartemisinin-PiperaquineLumefantrine regimenAdverse eventsCombination regimensSulfadoxine-pyrimethamineRandomized comparisonTreatment failureNew regimenRecurrent malariaAntimalarial therapyTreatment groupsArtemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial
Zongo I, Dorsey G, Rouamba N, Tinto H, Dokomajilar C, Guiguemde R, Rosenthal P, Ouedraogo J. Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. The Lancet 2007, 369: 491-498. PMID: 17292769, DOI: 10.1016/s0140-6736(07)60236-0.Peer-Reviewed Original ResearchConceptsUncomplicated falciparum malariaTreatment failureUncomplicated malariaArtemether-lumefantrineRecurrent parasitaemiaFalciparum malariaNew infectionsArtemisinin-based combination treatmentLate treatment failureEarly treatment failureNon-inferiority trialSymptomatic malariaEffective regimensPrimary endpointCombination regimensStandard dosesAvailable regimenCombination treatmentDrug susceptibilityPatientsAmodiaquineMalarial treatmentMalariaRegimensBobo-Dioulasso